Observed Signal · Sep 7, 2026 · Strategy · Source: Modern Retail · Impact: 2/5 · Sentiment: Positive
Brands Use Clinical Research as Growth Engine
Supplement and cleaning brands like AG1, Ritual, and Blueland are increasingly funding their own clinical research to differentiate products, boost advertising performance, and gain retail shelf space. These companies conduct or commission studies published in peer-reviewed journals, using findings to support marketing claims and product development. For instance, AG1 committed $20 million to research, while Ritual has invested over $5 million in studies. Such research helps brands combat misinformation, appeal to data-driven consumers, and satisfy wholesale buyers demanding third-party validation. Although there is no official FTC definition of 'clinical,' companies follow guidelines requiring competent scientific evidence for health claims. This strategy serves as a long-term brand investment, with executives noting higher-performing ads and stronger retail positioning as outcomes.
Highlights a growing trend among consumer brands to use clinical research for differentiation, but is not directly related to AdTech or MarTech infrastructure.
MARKET SIGNALS
Track AG1 Signals & Strategic Shifts
Polaris7 connects regulatory filings, primary sources, leadership changes, and M&A activity into structured intelligence. Set up your Polaris7 workspace to monitor relevant companies in your executive briefing.
- Verified primary sources
- Automated briefings
- Instant watchlist setup
Key Takeaways & Evidence Grounding
- AG1 committed $20 million to support three years of gut health and nutrient gap research.
- Ritual has invested at least $5 million in clinical studies and employed up to 20 full-time positions for research.
- Ritual completed at least five clinical studies, three peer-reviewed and published.
- Blueland commissioned a study on PVA microplastics published in an international journal.
- A 2024 Citruslabs survey found 85% of consumers are influenced by scientific claims.
Connected Companies & Entities
“AG1 launched an upgraded formula, AG1 NextGen, after running four clinical trials, and committed $20 million to research.”
Ontology Mapping & Concepts
Related Market Signals & Shifts
Recent verified developments and strategic activity across this market segment.
Consumer Healthcare Brands Embrace CPG Media Strategies
Consumer healthcare brands are increasingly adopting CPG-style media strategies to adapt to shifting consumer behavior and regulatory changes favoring OTC drugs. OTC sales rose to $58.2 billion in 2025, and the FDA has signaled openness to more prescription-to-OTC switches. Opella, spun out of Sanofi, exemplifies this trend, investing heavily in retail media, creator marketing, paid social, and search, with 60% of media investments now in digital channels. The company has built an 85-person in-house team using generative AI for creative production and brought programmatic and search in-house to boost ROI. Other companies like Kenvue and Hims & Hers are also adopting similar approaches. The shift brings challenges, including navigating retail media frictions and balancing long-term brand building with measurable performance, a balancing act CPG marketers already struggle with. AI search is also emerging as a key gateway to health information, requiring brands to monitor LLM citations.
Brand Expression Differentiates Brands in Age of AI
Adweek publishes an interview with Deena Bahri, CMO of Nutrafol, arguing that brand expression and creative positioning are the primary differentiators as AI levels access to performance marketing tools. Bahri describes her path from customer to CMO, Nutrafol’s move from fear-based to empowerment-driven messaging, and the company’s investments in clinical validation and transparency (including more than 25 clinical studies, NSF Sport Certification, and hiring a chief medical officer). The piece advises marketers to shift from lower-funnel performance tactics to full-funnel brand building and to use scientific credibility and authentic voice to build long-term trust and subscription-led lifetime value. Published by Adweek on 2026-06-05.
BrandRank.AI Launches Brand Risk Monitor to Trace Unfavorable AI Answers Back to Their Sources
BrandRank.AI announced the launch of Brand Risk Monitor, a source-level intelligence capability that traces unfavorable AI answers back to government, regulatory, news and independent sources. The platform introduces a Venom Score to measure claim severity and propagation likelihood, along with a Composite Risk Score, seven damage categories, source-level evidence trails and signal-decay intelligence. The capability is available now within the BrandRank.AI platform.
WATCHLIST & BRIEFINGS
Receive future signals for AG1 & competitors in your briefing
Stay ahead of material M&A deals, leadership changes, account wins, and product rollouts. Polaris7 connects primary filings, company newsrooms, and trade reporting directly into your executive briefing.
- Regular primary-source checks
- Structured Watchlist briefings
- Preserves current context
Market Signal Monitoring
Follow affected companies in Polaris7 with regular source checks and structured Watchlist briefings.
Monitor AG1
Follow affected companies in Polaris7 with regular source checks and structured Watchlist briefings.
